Summary
The pharmacokinetics of tiapride were determined at steady-state in 5 patients with tardive dyskinesia and 2 patients with Huntington's disease given tiapride 100 mg t.i.d. for 7 days. The maximum serum concentration of tiapride of 1.47±0.35 µg/ml was reached after 1.4±0.67 h. The half-life time of elimination was 229±41 min. About 50% of the dose of tiapride was excreted unchanged by the kidney. Neither protein binding nor glucuronide, sulphate or acetyl conjugation was observed. Renal clearance in the patients appeared to be lower but the other pharmacokinetic parameters did not differ from previous findings in healthy young volunteers.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Buruma OJS, Roos RAC, Bruyn GW, Kemp B, v.d. Velde EA (1982) Tiapride in the treatment of tardive dyskinesia. Acta Neurol Scand 65: 38–44
Chouza C, Romero S, Lorenzo J, Camano JL, Fontana AP, Alterwain P, Cibils D, Gaudiano J, Feres S, Solana J (1982) Traitement des dyskinésies par le tiapride. Semin Hôp Paris 58: 725–733
Lees AJ, Lander CM, Stern GM (1979) Tiapride in levodopa-induced involuntary movements. J Neurol Neurosurg Psychiatry 42: 380–383
Lipcsey A, Nagy E (1982) Expérience clinique du tiapride en neurologie. Semin Hôp Paris 58: 867–871
Miletto G, Julou M (1981) Le tiapride en neurologie et en psychiatrie chez la personne âgée. Semin Hôp Paris 57: 1833–1836
Nielsen BM (1983) Tiapride in levodopa-induced involuntary movements. Acta Neurol Scand 67: 372–375
Pollak P, Gaio JH, Hommel M, Pellat J, Perret J (1985) Effects of tiapride in tardive dyskinesia. Psychopharmacology 85: 236–239
Rey E, d'Athis Ph, Richard MO, de Lauture D, Olive G (1982) Pharmacokinetics of tiapride and absolute bioavailability of three extravascular forms. Int J Clin Pharmacol Ther Toxicol 20: 62–67
Roos RAC, Buruma OJS, Bruyn GW, Kemp B, v.d. Velde EA (1982) Tiapride in the treatment of Huntington's chorea. Acta Neurol Scand 65: 45–50
Rust M (1983) Anwendung von Tiaprid bei persistierenden Spätdyskinesien als Folge einer Neuroleptika-Behandlung. Munch Med Wochenschr 125: 461–462
Strolin-Benedetti M, Donath A, Frigerio A, Morgan KT, Lavelle C, Malnoe A (1978) Absorption, élimination et métabolisme du tiapride, (FLO, 1347), médicament neuroleptique, chez le rat, le chien et l'homme. Ann Pharm Franç 36: 279–288
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Roos, R.A.C., de Haas, E.J.M., Buruma, O.J.S. et al. Pharmacokinetics of tiapride in patients with tardive dyskinesia and Huntington's disease. Eur J Clin Pharmacol 31, 191–194 (1986). https://doi.org/10.1007/BF00606657
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00606657